CA3136328A1 - Prophylactic efficacy of serotonin 4 receptor agonists against stress - Google Patents
Prophylactic efficacy of serotonin 4 receptor agonists against stress Download PDFInfo
- Publication number
- CA3136328A1 CA3136328A1 CA3136328A CA3136328A CA3136328A1 CA 3136328 A1 CA3136328 A1 CA 3136328A1 CA 3136328 A CA3136328 A CA 3136328A CA 3136328 A CA3136328 A CA 3136328A CA 3136328 A1 CA3136328 A1 CA 3136328A1
- Authority
- CA
- Canada
- Prior art keywords
- stress
- mice
- administered
- ht4r
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831517P | 2019-04-09 | 2019-04-09 | |
| US62/831,517 | 2019-04-09 | ||
| US201962857075P | 2019-06-04 | 2019-06-04 | |
| US62/857,075 | 2019-06-04 | ||
| US201962910859P | 2019-10-04 | 2019-10-04 | |
| US62/910,859 | 2019-10-04 | ||
| PCT/US2020/027321 WO2020210393A1 (en) | 2019-04-09 | 2020-04-08 | Prophylactic efficacy of serotonin 4 receptor agonists against stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3136328A1 true CA3136328A1 (en) | 2020-10-15 |
Family
ID=72750568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3136328A Pending CA3136328A1 (en) | 2019-04-09 | 2020-04-08 | Prophylactic efficacy of serotonin 4 receptor agonists against stress |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220031684A1 (https=) |
| EP (1) | EP3952852A4 (https=) |
| JP (1) | JP7683882B2 (https=) |
| CN (1) | CN113924087A (https=) |
| AU (1) | AU2020271839B2 (https=) |
| CA (1) | CA3136328A1 (https=) |
| MX (1) | MX2021012394A (https=) |
| WO (1) | WO2020210393A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7821116B2 (ja) * | 2020-04-07 | 2026-02-26 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法 |
| EP4577305A2 (en) * | 2022-08-25 | 2025-07-02 | 1/1The Trustees Of Columbia University In The City Of New York | Compositions and methods for the treatment of alzheimer's disease and other neurogenerative disease |
| CN118105081B (zh) * | 2024-03-04 | 2025-02-11 | 天津大学 | 一种情绪状态与神经电生理状态调节装置、验证系统及方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2846559B1 (fr) * | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US20090170899A1 (en) | 2004-09-14 | 2009-07-02 | Guy Debonnel | Stimulators of 5-HT4 receptors and uses thereof |
| EP2640398A4 (en) | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHOD FOR TREATING CHRONIC OR BZW. NON-RELIABLE PAIN AND / OR INCREASE OF PATIENT PAIN THRESHOLD AND PHARMACEUTICAL COMPOSITION FOR USE THEREOF |
| US11110070B2 (en) | 2015-11-17 | 2021-09-07 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms |
-
2020
- 2020-04-08 CN CN202080042252.4A patent/CN113924087A/zh active Pending
- 2020-04-08 WO PCT/US2020/027321 patent/WO2020210393A1/en not_active Ceased
- 2020-04-08 EP EP20786878.7A patent/EP3952852A4/en active Pending
- 2020-04-08 MX MX2021012394A patent/MX2021012394A/es unknown
- 2020-04-08 JP JP2021560628A patent/JP7683882B2/ja active Active
- 2020-04-08 AU AU2020271839A patent/AU2020271839B2/en active Active
- 2020-04-08 CA CA3136328A patent/CA3136328A1/en active Pending
-
2021
- 2021-10-05 US US17/494,218 patent/US20220031684A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7683882B2 (ja) | 2025-05-27 |
| AU2020271839B2 (en) | 2025-04-24 |
| US20220031684A1 (en) | 2022-02-03 |
| EP3952852A1 (en) | 2022-02-16 |
| MX2021012394A (es) | 2022-01-19 |
| CN113924087A (zh) | 2022-01-11 |
| WO2020210393A1 (en) | 2020-10-15 |
| EP3952852A4 (en) | 2023-01-04 |
| JP2022527865A (ja) | 2022-06-06 |
| AU2020271839A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Petroianu et al. | Neuropathic pain: Mechanisms and therapeutic strategies | |
| Sales et al. | Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels | |
| US11110070B2 (en) | Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms | |
| Mitchell et al. | Good night and good luck: norepinephrine in sleep pharmacology | |
| Wolff et al. | Ketamine: from medicine to misuse | |
| US12239614B2 (en) | Pharmacological prophylactics against stress-induced affective disorders in females | |
| US20220031684A1 (en) | Prophylactic efficacy of serotonin 4 receptor agonists against stress | |
| JP7821116B2 (ja) | ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法 | |
| US20220071932A1 (en) | Compositions and Methods Against Stress-Induced Affective Disorders and Their Associated Symptoms | |
| US20090082341A1 (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER | |
| US20130302352A1 (en) | Methods for the prevention and/or treatment of memory impairment | |
| US20200316087A1 (en) | Novel combination therapy for anxiety disorders, epilepsy, and pain | |
| Harun et al. | The neurobiological basis of pharmacological approaches for patients with traumatic brain injury | |
| WO2023215338A1 (en) | Compositions and methods for treating cluster headache | |
| WO2023215344A2 (en) | Compositions and methods for treating cluster-tic syndrome | |
| WO2023215342A1 (en) | Compositions and methods for treating trigeminal neuralgia | |
| Abd-Elsayed et al. | Selective NaV1. 8 Inhibition for Pain Management: Current Evidence and Future Potential of Suzetrigine | |
| Brandt | Critical review report: 3-Methylmethcathinone (3-MMC) | |
| Di Martino et al. | Cannabidiol for the Treatment of Neurodevelopmental Disorders: Focus on Schizophrenia and Autism | |
| Davis et al. | Therapeutic goals for the management of posttraumatic stress disorder (PTSD) most commonly innightmares, intrusive irrita | |
| Davis et al. | Therapeutic goals for the management commonly innightmares | |
| Cameron | Psychedelics and novel non-hallucinogenic analogs for treating neuropsychiatric disorders | |
| Linge Méndez et al. | Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors | |
| Cruz | Impact of Psychoactive Drugs on Mental Health | |
| Posner | Novel melatonin MT1 receptor agonists as antidepressants: In vivo electrophysiological and behavioural characterization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240321 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250328 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250404 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250404 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250725 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250731 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250818 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250818 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20251118 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251119 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251215 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251215 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251215 |